Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) EBIT: 2024-2025

Historic EBIT for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$80.0 million.

  • Kura Oncology's EBIT fell 33.59% to -$80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$239.8 million, marking a year-over-year change of. This contributed to the annual value of -$193.2 million for FY2024, which is 16.52% down from last year.
  • As of Q3 2025, Kura Oncology's EBIT stood at -$80.0 million, which was down 10.09% from -$72.7 million recorded in Q2 2025.
  • Kura Oncology's 5-year EBIT high stood at -$22.5 million for Q4 2024, and its period low was -$80.0 million during Q3 2025.
  • Over the past 2 years, Kura Oncology's median EBIT value was -$59.9 million (recorded in 2024), while the average stood at -$58.7 million.
  • Data for Kura Oncology's EBIT shows a maximum YoY plummeted of 33.59% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's EBIT stood at -$22.5 million in 2024, then plummeted by 33.59% to -$80.0 million in 2025.
  • Its last three reported values are -$80.0 million in Q3 2025, -$72.7 million for Q2 2025, and -$64.7 million during Q1 2025.